PharmaCyte Biotech, Inc. (PMCB) — Institutional Holders, Q2 2026

32 institutional investment managers reported a PMCB position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $586.2K. Every filer is listed below, ranked by position value. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.

PMCB in Q2 2026: what funds did

Funds that filed a 13F for both Q1 2026 and Q2 2026, by what they did with the common stock. Share counts are adjusted for any split between the two quarters; dollar figures are the change in shares at this quarter’s price.

New positions

4

Added to

6

Trimmed

10

Sold out

7

Biggest buyers

  1. SUSQUEHANNA INTERNATIONAL GROUP, LLPNew · +44,853 sh+$34.5K
  2. JANE STREET GROUPAdded · +18,534 sh+$14.3K
  3. COMMONWEALTH EQUITY SERVICESAdded · +9,942 sh+$7.7K
  4. VANGUARD CAPITAL MANAGEMENTAdded · +5,311 sh+$4.1K
  5. BARCLAYS PLCNew · +192 sh+$148.00

Biggest sellers

  1. CITADEL ADVISORSTrimmed · -76,166 sh-$58.6K
  2. GEODE CAPITAL MANAGEMENTTrimmed · -71,413 sh-$55.0K
  3. Virtu FinancialSold out · -37,532 sh-$28.9K
  4. SIMPLEX TRADINGSold out · -19,940 sh-$15.4K
  5. RENAISSANCE TECHNOLOGIESTrimmed · -18,513 sh-$14.3K

PMCB 13F holders ranked 1–32 of 32

Institutional investors reporting a position in PharmaCyte Biotech, Inc. on SEC Form 13F-HR for Q2 2026, ranked by reported value.
InstitutionValueQoQ
CITADEL ADVISORS#1 · 283,381 sh$218.2K-21.2%
GEODE CAPITAL MANAGEMENT#2 · 124,247 sh$95.7K-36.5%
VANGUARD CAPITAL MANAGEMENT#3 · 56,778 sh$43.7K+10.3%
SUSQUEHANNA INTERNATIONAL GROUP, LLP#4 · 44,853 sh$34.5KNew
RENAISSANCE TECHNOLOGIES#5 · 37,987 sh$29.3K-32.8%
XTX Topco Ltd#6 · 34,180 sh$26.3K-34.7%
NORTHERN#7 · 32,624 sh$25.1K-8.4%
JANE STREET GROUP#8 · 30,064 sh$23.1K+160.7%
Schonfeld Strategic Advisors#9 · 26,926 sh$20.7K-0.3%
VANGUARD FIDUCIARY#10 · 23,452 sh$18.1K0.0%
EQUITEC PROPRIETARY MARKETS#11 · 22,227 sh$17.1K0.0%
COMMONWEALTH EQUITY SERVICES#12 · 20,255 sh$15.6K+96.4%
HRT FINANCIAL#13 · 15,451 sh$11.0K-37.5%
Tower Research Capital (TRC)#14 · 4,888 sh$3.8K0.0%
UBS Group AG#15 · 4,142 sh$3.2K-8.3%
GROUP ONE TRADING, L.P.#16 · 500 sh$385.00-72.0%
OSAIC#17 · 303 sh$232.00+0.3%
BARCLAYS PLC#18 · 192 sh$148.00New
Sachetta#19 · 14 sh$11.000.0%
SBI Securities , Ltd.#20 · 6 sh$5.00+100.0%
BFSG#21 · 5 sh$4.000.0%
CoreCap Advisors#22 · 4 sh$3.00New
FINANCIAL CONSULATE#23 · 2 sh$2.000.0%
NewEdge Advisors#24 · 2 sh$2.00New
CALDWELL SUTTER CAPITAL#25 · 2 sh$2.000.0%
HARBOUR INVESTMENTS#26 · 3 sh$2.000.0%
MORGAN STANLEY#27 · 2 sh$2.00+100.0%
Johnson Financial Group#28 · 1 sh$1.000.0%
MCF Advisors#29 · 1 sh$1.000.0%
BlackRock#30 · 1 sh$1.000.0%
Covestor Ltd#31 · 275 sh$0.000.0%
HUNTINGTON NATIONAL BANK#32 · 1 sh$0.000.0%

Funds that sold out of PMCB in Q2 2026 (7)

Held PMCB at the end of Q1 2026 and filed a Q2 2026 13F without it. Not in the list above, because they no longer hold it. Largest prior position first.

Institutions that held PMCB in Q1 2026 and reported no position in Q2 2026.
InstitutionValue in Q1 2026
Virtu Financial37,532 sh$25.0K
SIMPLEX TRADING19,940 sh$13.3K
TWO SIGMA SECURITIES16,360 sh$10.9K
Ground Swell Capital11,527 sh$7.7K
Western Wealth Management13 sh$9.00
Abound Wealth Management1 sh$1.00
Fortitude Family Office1 sh$1.00

Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.